Agios Pharmaceuticals Inc
NASDAQ:AGIO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
21.32
60.46
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AGIO stock under the Base Case scenario is 18.811 USD. Compared to the current market price of 55.515 USD, Agios Pharmaceuticals Inc is Overvalued by 66%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Agios Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AGIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Agios Pharmaceuticals Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Agios Pharmaceuticals Inc
Balance Sheet Decomposition
Agios Pharmaceuticals Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 1B |
Receivables | 3.1m |
Other Current Assets | 66.3m |
Non-Current Assets | 717.6m |
Long-Term Investments | 655.9m |
PP&E | 57.7m |
Other Non-Current Assets | 4.1m |
Current Liabilities | 119.5m |
Accounts Payable | 17.1m |
Accrued Liabilities | 49.6m |
Other Current Liabilities | 52.7m |
Non-Current Liabilities | 45.7m |
Other Non-Current Liabilities | 45.7m |
Earnings Waterfall
Agios Pharmaceuticals Inc
Revenue
|
32.9m
USD
|
Cost of Revenue
|
-3.5m
USD
|
Gross Profit
|
29.4m
USD
|
Operating Expenses
|
-436.4m
USD
|
Operating Income
|
-407m
USD
|
Other Expenses
|
1.1B
USD
|
Net Income
|
674.3m
USD
|
Free Cash Flow Analysis
Agios Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Agios achieved $9 million in net revenue from PYRUKYND, marking a 22% increase year-over-year. The company noted muted growth ahead, with focus on launching in thalassemia by 2025. They also received $1.1 billion in milestone payments following FDA approval of vorasidenib, enhancing their strong cash position of approximately $1.7 billion. Agios aims to file for expanded indications in thalassemia by year-end and has completed enrollment for the Phase III RISE UP study for sickle cell disease, targeting therapeutic launches in 2026. They remain committed to cost-effective strategies while preparing for significant market opportunities.
What is Earnings Call?
AGIO Profitability Score
Profitability Due Diligence
Agios Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Agios Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
AGIO Solvency Score
Solvency Due Diligence
Agios Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Agios Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AGIO Price Targets Summary
Agios Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for AGIO is 56.1 USD with a low forecast of 51.51 USD and a high forecast of 59.85 USD.
Dividends
Current shareholder yield for AGIO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AGIO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 390 full-time employees. The company went IPO on 2013-07-24. The firm's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The firm is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.
Contact
IPO
Employees
Officers
The intrinsic value of one AGIO stock under the Base Case scenario is 18.811 USD.
Compared to the current market price of 55.515 USD, Agios Pharmaceuticals Inc is Overvalued by 66%.